Marieke Van Son

Ms. Marieke Van Son

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
TSTaimur T. Shah
Taimur T. Shah
DRDeepika Reddy
Deepika Reddy
MPMax Peters
Max Peters
DBDaniel Ball
Daniel Ball
NKNa Hyun Kim
Na Hyun Kim
MWMathias Winkler
Mathias Winkler

1 May 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
MSMarieke Van Son
Marieke Van Son
MPMax Peters
Max Peters
MMMarinus A. Moerland
Marinus A. Moerland
JLJan J.W. Lagendijk
Jan J.W. Lagendijk
WEWietse S.C. Eppinga
Wietse S.C. Eppinga
JZJochem R.N. van der Voort van Zyp
Jochem R.N. van der Voort van Zyp

1 May 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
MSMarieke Van Son
Marieke Van Son
MPMax Peters
Max Peters
DRDeepika Reddy
Deepika Reddy
TSTaimur T. Shah
Taimur T. Shah
FHFeargus Hosking-Jervis
Feargus Hosking-Jervis
AFAlison Falconer
Alison Falconer

3 December 2018 in Cancers
Verified
Journal Article
Open access
PDF file
MSMarieke Van Son
Marieke Van Son
MPMax Peters
Max Peters
MMMarinus Moerland
Marinus Moerland
LKLinda Kerkmeijer
Linda Kerkmeijer
JLJan Lagendijk
Jan Lagendijk
JZJochem Van der Voort van Zyp
Jochem Van der Voort van Zyp
Over the last decades, primary prostate cancer radiotherapy saw improving developments, such as more conformal dose administration and hypofractionated treatment regimens. Still, prostate cancer recurrences after whole-gland radiotherapy remain common, especially in patients with intermediate- to high-risk disease. The vast majority of these patients are treated palliatively with androgen deprivation therapy (ADT), which exposes them to harmful side-effects and is only effective for a limited amount of time. For patients with a localized recurrent tumor and no signs of metastatic disease, local treatment with curative intent seems more rational. However, whole-gland salvage treatments such as salvage radiotherapy or salvage prostatectomy are associated with significant toxicity and are, therefore, uncommonly performed. Treatments that are solely aimed at the recurrent tumor itself, thereby better sparing the surrounding organs at risk, potentially provide a safer salvage treatment option in terms of toxicity. To achieve such tumor-targeted treatment, imaging developments have made it possible to better exclude metastatic disease and accurately discriminate the tumor. Currently, focal salvage treatment is being performed with different modalities, including brachytherapy, cryotherapy, high-intensity focused ultrasound (HIFU), and stereotactic body radiation therapy (SBRT). Oncologic outcomes seem comparable to whole-gland salvage series, but with much lower toxicity rates. In terms of oncologic control, these results will improve further with better understanding of patient selection. Other developments, such as high-field diagnostic MRI and live adaptive MRI-guided radiotherapy, will further improve precision of the treatment.

8 September 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
DRDeepika Reddy
Deepika Reddy
MSMarieke Van Son
Marieke Van Son
MPMax Peters
Max Peters
MTMariana Bertoncelli Tanaka
Mariana Bertoncelli Tanaka
TDTim Dudderidge
Tim Dudderidge
HAHashim Uddin Ahmed
Hashim Uddin Ahmed
Focal therapy treats individual areas of tumour in non-metastatic prostate cancer in patients unsuitable for active surveillance. The aim of this work was to evaluate the cost-effectiveness of focal therapy versus prostatectomy and external beam radiotherapy (EBRT). A Markov cohort health state transition model with four health states (stable disease, local recurrence, metastatic disease and death) was created, evaluating costs and utilities over a 10-year time horizon for patients diagnosed with non-metastatic prostate cancer. National Health Service (NHS) for England perspective was used, based on direct healthcare costs. Clinical transition probabilities were derived from prostate cancer registries in patients undergoing radical prostatectomy, EBRT and focal therapy using cryotherapy (Boston Scientific) or high-intensity focused ultrasound (HIFU) (Sonablate). Propensity score matching was used to ensure at-risk populations were comparable. Variables included age, prostate-specific antigen (PSA), International Society of Urological Pathology (ISUP) grade group, maximum cancer core length (mm), T-stage and year of treatment. Focal therapy was associated with a lower overall cost and higher quality adjusted life year (QALY) gains than either prostatectomy or EBRT, dominating both treatment strategies. Positive incremental net monetary benefit (NMB) values confirm focal therapy as cost effective versus the alternatives at a willingness to pay (WTP) threshold of £30,000/QALY. One-way deterministic sensitivity analyses revealed consistent results. Data used to calculate the transition probabilities were derived from a limited number of hospitals meaning that other potential treatment options were excluded. Limited data were available on later outcomes and none on quality of life data, therefore, literature-based estimates were used. Cost-effectiveness modelling demonstrates use of focal therapy (cryotherapy or HIFU) is associated with greater QALY gains at a lower overall cost than either radical prostatectomy or EBRT, representing good value for money in the NHS.

19 September 2018 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
MSMarieke Van Son
Marieke Van Son
MLM. T. W. T. Lock
M. T. W. T. Lock
MPMax Peters
Max Peters
EPE. E. Fransen van de Putte
E. E. Fransen van de Putte
RMRichard P. Meijer
Richard P. Meijer
To compare open surgical anastomotic revision with endourological techniques for the treatment of ureteroenteric strictures in patients with urinary diversions.